Cooperative Agreement U24CA204781

This Project Grant award of $275,956 from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program aims to develop an engineered cyber-physical system that combines advanced biological models with artificial intelligence methods for predictive, automated screening of anti-cancer drugs and optimization of their dosing. The key products and services to be delivered under this award include: 1) Adoption of 3D bioprinting to generate vascularized ductal...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $391,703 to The Regents of the University of California, San Francisco (UCSF) to develop rapid, sensitive, and reproducible platforms for screening drugs in a preclinical setting using patient-derived organoids (PDOs). The project aims to improve the uniformity, scalability, and physiological relevance of PDOs to enable more accurate prediction of drug efficacy, with a...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $654,197 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on pancreatic cancer patient-derived xenograft (PDX) tumor models. The research aims to: Define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how...

The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...

The National Cancer Institute (NCI) awarded PDX Pharmaceuticals Inc. a $410,652 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance the commercialization readiness of their nanoparticle-based immunotherapy, ARAC-02, for the treatment of non-small cell lung cancer (NSCLC). The funding supports two key activities: 1) Pursuing international patent protection for the company's PDX-NP nanoparticle platform and ARAC-02 compositions, and 2) Initiating...

This $627,833 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The goal is to assess the fidelity of these preclinical models through comparative analyses. The University of Texas Southwestern Medical Center, the prime awardee, will work with Duke University as a sub-awardee to...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $119,172 to The Leland Stanford Junior University to conduct research aimed at "Harnessing Multi-Modal and Multi-Omics Data Integration to Decipher Therapeutic Response in Non-Small Cell Lung Cancer." The key objectives are to: (1) Identify clinically relevant spatial cellular architectures contributing to therapeutic response; (2) Develop an image-based digital cytometer to...

This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...